HER-2/NEU (HER2) peptide based vaccine with FLT3 ligand (FL) +/- GM-CSF as an adjuvant.

被引：0
|
作者：
Disis, ML
Rinn, K
Davis, D
Caron, D
Schiffman, K
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Immunex Corp, Seattle, WA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1961
引用
收藏
页码：456A / 456A
页数：1
相关论文
共 50 条
  • [21] The Clinical Benefit and Safety of Boosting the HER2 Peptide Vaccine (GP2+GM-CSF) in the Adjuvant Setting to Prevent Breast Cancer Recurrence
    Schneble, E.
    Berry, J. S.
    Trappey, A. F.
    Hale, D. F.
    Vreeland, T. J.
    Sears, A.
    Clifton, G. T.
    Ponniah, S.
    Papamichael, M.
    Perez, S.
    Peoples, G. E.
    Mittendorf, E.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S45 - S46
  • [22] Pilot Study of an HLA-A2 Peptide Vaccine Using Flt3 Ligand as a Systemic Vaccine Adjuvant
    Douglas G. McNeel
    Keith L. Knutson
    Kathy Schiffman
    Donna R. Davis
    Dania Caron
    Mary L. Disis
    Journal of Clinical Immunology, 2003, 23 : 62 - 72
  • [23] Pilot study of an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant
    McNeel, DG
    Knutson, KL
    Schiffman, K
    Davis, DR
    Caron, D
    Disis, ML
    JOURNAL OF CLINICAL IMMUNOLOGY, 2003, 23 (01) : 62 - 72
  • [24] HER2/neu和GM-CSF共转染树突状细胞的免疫杀伤研究
    唐三元
    黄卫国
    伍尤华
    戴文香
    江青山
    细胞与分子免疫学杂志, 2008, (01) : 76 - 79
  • [25] Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants
    Mossman, SR
    Evans, LS
    Fang, H
    Staas, J
    Tice, T
    Raychaudhuri, S
    Grabstein, KH
    Cheever, MA
    Johnson, ME
    VACCINE, 2005, 23 (27) : 3545 - 3554
  • [26] Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
    Disis, ML
    Gooley, TA
    Rinn, K
    Davis, D
    Piepkorn, M
    Cheever, MA
    Knutson, KL
    Schiffman, K
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2624 - 2632
  • [27] Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein
    Dela Cruz, JS
    Morrison, SL
    Penichet, ML
    VACCINE, 2005, 23 (39) : 4793 - 4803
  • [28] Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine
    Greene, Julia M.
    Schneble, Erika J.
    Litton, Jennifer K.
    Martin, Jonathon
    Trappey, Alfred F.
    Berry, John S.
    Vreeland, Timothy J.
    Hale, Diane F.
    Clifton, Guy T.
    Ardavannis, Alexandros
    Papamichail, Michael
    Perez, Sonia
    Ponniah, Sathibalan
    Mittendorf, Elizabeth A.
    Peoples, George E.
    CANCER RESEARCH, 2015, 75
  • [29] Peptide-based vaccination against the HER-2/neu oncogenic protein
    Boer R.
    Breast Cancer Research, 2 (1)
  • [30] Vaccination against Her-2/neu, with focus on peptide-based vaccines
    Tobias, J.
    Garner-Spitzer, E.
    Drinic, M.
    Wiedermann, U.
    ESMO OPEN, 2022, 7 (01)
12345